Sickle Cell Treatment: FDA Approves Gene Therapies for Recurrent Vaso-Occlusive Crises

Listen to this News

Highlights:

• FDA approves CASGEVY� and LYFGENIA�, marking a pivotal moment in sickle cell disease treatment
• The use of CRISPR technology and gene editing in sickle cell patients - transforming the shape of red blood cells and preventing painful crises
• Children's Hospital of Philadelphia (CHOP) emerges as a qualified treatment center, offering hope to patients with sickle cell disease through innovative gene therapies

Sickle cell treatment enters a transformative era with groundbreaking gene therapies, CASGEVY� and LYFGENIA�. The Food and Drug Administration (FDA) has given its nod to CASGEVY� (exagamglogene autotemcel) and LYFGENIA� (lovotibeglogene autotemcel), marking the inaugural approval of gene therapies for treating sickle cell disease in patients aged 12 and older facing recurrent vaso-occlusive crises (VOCs) (1^✔).

Notably, Children's Hospital of Philadelphia (CHOP), among other sites, played a pivotal role in the rigorous clinical trials leading to this groundbreaking achievement. CHOP stands as a Qualified Treatment Center, offering LYFGENIA manufactured by bluebird bio, and also plans to provide CASGEVY, manufactured by Vertex Pharmaceuticals.

Treatment of Sickle Cell Anemia

"For many years, a bone marrow transplant has been the only transformative option for treating patients with sickle cell disease, and a limited one, as not all patients have a suitable donor," remarked Dr. Alexis A. Thompson, Chief of the Division of Hematology at Children's Hospital of Philadelphia. "Now, after decades of limited progress in treating sickle cell disease, we have reached a historical moment with two new gene therapies."

What is Sickle Cell Anemia?

Sickle cell disease, characterized by deformed blood cells causing blockages in blood vessels, leads to intense pain, strokes, organ damage, and potentially shortened lives.

‘A new era in sickle cell treatment! FDA gives the green light to CASGEVY� and LYFGENIA� gene therapies, a breakthrough moment in healthcare. #sicklecell #genetherapy ’

Newly Approved Gene Therapies for Sickle Cell Anemia

The newly approved gene therapies leverage advanced DNA editing techniques, including CRISPR technology, to enable patients to produce a different form of hemoglobin in their red blood cells, preventing the characteristic crescent shape apparent in sickle cell disease and eliminating pain episodes in almost all patients.

CASGEVY, developed with CRISPR technology, marks a significant milestone as the first FDA-approved therapy utilizing this cutting-edge genetic editing approach. Conversely, LYFGENIA focuses on treating the underlying cause of sickle cell disease by adding a functional gene that enables the production of adult hemoglobin, preventing its crescent-shape formation.

Treating Sickle Cell Anemia with Gene Therapy

"In clinical trials with CASGEVY, we have seen the elimination of painful vaso-occlusive crises in more than 90% of patients and a complete elimination of VOC-related hospitalizations in all patients," stated Dr. Stephan A. Grupp, Section Chief of the Cellular Therapy and Transplant Section at CHOP. Dr. Grupp, one of the principal investigators in the clinical trials, emphasized the meaningful impact of the treatment on patients.

"As these therapies become available outside of the landmark clinical trials, we will carefully monitor each patient's progress," said Dr. Janet Kwiatkowski, Director of the Thalassemia Center at CHOP. "CHOP's extensive experience in studying and treating patients with these therapies will help ensure we get the best outcomes for these patients."

CHOP's Comprehensive Center for the Cure of Sickle Cell Disease and Other Red Blood Cell Disorders (CuRED) program, established to take the treatment of these disorders beyond supportive care, offers tailored evaluation and cutting-edge treatment. Gene therapy recipients are treated by CHOP's Cell Therapy and Transplant Section.

"Gene therapy requires specialized centers, and thanks to the work being done in our CuRED Program, CHOP is one such center," stated Dr. Thompson. "The hope is that, as we gain more experience using this technology, more centers will come online, potentially reaching communities worldwide."

CHOP is actively exploring innovative treatments for sickle cell disease, including in vivo modification of blood stem cells and transcriptional regulation of fetal hemoglobin to improve oxygen transfer. As a global leader in cell and gene therapies, CHOP's contributions include FDA-approved therapies such as Kymriah and Luxturna, underscoring its commitment to pushing the boundaries of medical possibilities. The historic FDA approvals for sickle cell disease signal a new era, offering hope for improved patient outcomes and advancements in gene therapy worldwide.

Reference:

1. FDA Approves Two Gene Therapies for Sickle Cell Disease - (https:www.chop.edu/news/fda-approves-two-gene-therapies-sickle-cell-disease)

Source: Medindia

Cite this Article ⇣⇡

Please use one of the following formats to cite this article in your essay, paper or report:

• APA

  Dr. Trupti Shirole. (2023, December 10). Sickle Cell Treatment: FDA Approves Gene Therapies for Recurrent Vaso-Occlusive Crises. Medindia. Retrieved on Dec 23, 2024 from https://www.medindia.net/news/healthwatch/sickle-cell-treatment-fda-approves-gene-therapies-for-recurrent-vaso-occlusive-crises-214476-1.htm.

• MLA

  Dr. Trupti Shirole. "Sickle Cell Treatment: FDA Approves Gene Therapies for Recurrent Vaso-Occlusive Crises". Medindia. Dec 23, 2024. <https://www.medindia.net/news/healthwatch/sickle-cell-treatment-fda-approves-gene-therapies-for-recurrent-vaso-occlusive-crises-214476-1.htm>.

• Chicago

  Dr. Trupti Shirole. "Sickle Cell Treatment: FDA Approves Gene Therapies for Recurrent Vaso-Occlusive Crises". Medindia. https://www.medindia.net/news/healthwatch/sickle-cell-treatment-fda-approves-gene-therapies-for-recurrent-vaso-occlusive-crises-214476-1.htm. (accessed Dec 23, 2024).

• Harvard

  Dr. Trupti Shirole. 2023. Sickle Cell Treatment: FDA Approves Gene Therapies for Recurrent Vaso-Occlusive Crises. Medindia, viewed Dec 23, 2024, https://www.medindia.net/news/healthwatch/sickle-cell-treatment-fda-approves-gene-therapies-for-recurrent-vaso-occlusive-crises-214476-1.htm.